Researchers have identified proteins behind bacterial mutation, paving the way for a sustainable treatment to bacterial diseases.
Researchers use a cocktail of bacteriophages to fight drug-resistant tuberculosis.
Human Mesenchymal Stem Cells found to favour the survival of tuberculosis bacteria, instead of fighting it, shows a recent study.
In a recent study, researchers from Pune, along with their collaborators in Chennai and the USA, have assessed the functioning of lungs after successful tuberculosis (TB) treatment. The study, published in the journal PLoS ONE, has shown the occurrence of lung defects and chronic obstructive pulmonary disease after tuberculosis treatment.
Researchers find familial dissimilarities in proteins from two species of Mycobacterium.
An international study, led by researchers from the USA, which also included researchers from India, have designed a point-of-care testing approach for individuals suffering from TB. The study, published in the journal Science Translational Medicine and supported in part by the Bill and Melinda Gates Foundation, proposes a rapid, cost-effective, and readily accessible triage test kit that can be used at the site of patient care.
In 2018, around 1.5 million people died from tuberculosis (TB) — an infectious disease that mainly affects the lungs. A major obstacle in the clinical treatment of TB is the long therapy time required to clear the infection. An infected patient needs to take antibiotics for over 6 to 9 months to prevent a relapse — a duration so long that many discontinue their medications.
Tuberculosis, caused by the bacteria Mycobacterium tuberculosis, is a leading cause of death worldwide. In 2017 alone, 10 million people across the globe were affected by the disease, and about 1.6 million succumbed to it.
